NorthStar to buy IBA accelerators for Mo-99 production

NorthStar Medical Radioisotopes has signed an agreement with proton therapy...Read more on AuntMinnie.comRelated Reading: IBA posts mixed 2018 financial results DOE to fund U.S. Mo-99 production NorthStar works to build Mo-99 production capacity IBA opens cyclotron center in India NorthStar names Estrem as CFO IBA's proton therapy system up and running in Japan
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

This article presents an overview of current indications for PT with emphasis on tumors in the head and neck region and the base of skull. Furthermore, a summary and discussion of relevant results and current developments are included. MATERIALS AND METHODS: The work comprises an evaluation of relevant studies and an overview of current issues related to PT of tumors in the areas of the head, neck, and base of skull. RESULTS: Overall, the studies on PT show promising results. In addition to dosimetric studies, clinical studies also point to advantages of PT, especially with regard to the reduction of side effects. ...
Source: HNO - Category: ENT & OMF Tags: HNO Source Type: research
Source: Australasian Physical and Engineering Sciences in Medicine - Category: Biomedical Engineering Source Type: research
Proteus 235 The Proton Therapy System - Proteus 235 (brand names: Proteus Plus and Proteus ONE) is a medical device designed to produce and deliver a proton beam for the treatment of patients with localized tumors and other conditions susceptible to treatment by radiation.
Source: Medical Device Recalls - Category: Medical Devices Source Type: alerts
CONCLUSION: Both full plan adaptation and simple dose restoration can increase OAR sparing besides better conforming to the target criteria compared to robust treatment planning. PMID: 32777242 [PubMed - as supplied by publisher]
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research
CONCLUSIONS: Visual acuity decline following radiotherapy for intracranial malignancies in children is rare. A dose of approximately 56 GyRBE to 0.1 cm3 results in an approximately 5% risk of visual acuity decline for children with suprasellar or optic pathway tumors. A dose to 0.1 cm3 of 56 GyRBE appears to be safe for children with tumors elsewhere in the brain. PMID: 32762400 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
This study compares a robust planning strategy to two online-adaptive IMPT strategies to determine the benefit of online adaptation.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
Compared to radiotherapy using photons, the superior beam properties of protons can be translated into two main strategies to obtain a clinical benefit: 1) dose escalation to improve local tumor control without increasing the risk of unacceptable radiation-induced toxicity, or 2) the sparing of healthy tissues with equivalent target dose to reduce the risk of radiation-induced side effects with similar tumor control. For the latter group of indications, the model-based approach was developed [1,2].
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
CONCLUSIONS: 4D dose reconstruction and accumulation enables the clinical estimation of actual exhibited interplay and motion effects. In the patients considered here, the loss of homogeneity caused by interplay and organ motion did not show systematic pattern and smeared out throughout the course of fractionated PBS-PT treatment. Dose degradation due to anatomical changes showed to be more severe and triggered treatment adaptations for five patients. PMID: 32768509 [PubMed - as supplied by publisher]
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research
CONCLUSION: Model-based selection of patients with HNC for proton therapy is clinically feasible. Approximately one third of HNC patients qualify for protons and these patients have the highest probability to benefit from protons in terms of toxicity prevention. PMID: 32768508 [PubMed - as supplied by publisher]
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research
Pencil beam scanned proton therapy (PBS PT) treatments of intrathoracic targets are associated with significant uncertainty. Treatment quality may be compromised by setup errors, range uncertainties, respiratory motion baseline shifts, anatomical changes, delivery inaccuracies and motion of various sources (e.g. respiration, cardiac motion, swallowing, etc.). More specifically, the relative motion between a thoracic target volume and the scanning proton beam can cause deviation of the delivered dose from the planned dose and is referred to as the interplay effect.
Source: Radiotherapy and Oncology - Category: Radiology Authors: Tags: Original Article Source Type: research
More News: India Health | Japan Health | Proton Therapy | Radiology